List of Excipients in Branded Drug NORTRIPTYLINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing NORTRIPTYLINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	AMMONIA
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	DIMETHICONE
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	FD&C YELLOW NO. 6
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	FERROSOFERRIC OXIDE
Teva Pharmaceuticals USA Inc	nortriptyline hydrochloride	0093-0810	GELATIN

What are the Most Frequently-Used Excipients in NORTRIPTYLINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ALCOHOL
29	ALUMINUM OXIDE
16	AMMONIA
1	ANHYDROUS CITRIC ACID
48	BENZYL ALCOHOL
48	BUTYLPARABEN
1	CHERRY

Nortriptyline Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nortriptyline hydrochloride is a mature, low-cost tricyclic antidepressant with established oral capsule and tablet use. The strongest commercial opportunities are differentiated oral liquids, pediatric and geriatric presentations, simplified dosing, improved swallowability, and supply-chain advantages rather than conventional generic entry. Excipient selection must address bitterness, dose uniformity, chemical stability, capsule or tablet performance, and the drug’s narrow therapeutic margin for some patients.

What dosage forms and excipient systems are used for nortriptyline hydrochloride?

Nortriptyline hydrochloride is marketed primarily as immediate-release oral capsules and tablets. U.S. reference-product labeling identifies Pamelor capsules in strengths including 10 mg, 25 mg, 50 mg, and 75 mg. Generic products use varying excipient systems, so the inactive-ingredient profile is product-specific (FDA, 2024a; DailyMed, 2024a).

Dosage form	Typical excipient system	Commercial relevance
Hard gelatin capsule	Lactose or other diluent, starch, talc, colloidal silicon dioxide, magnesium stearate, capsule shell colorants	Lowest development risk; commoditized
Immediate-release tablet	Microcrystalline cellulose, lactose or dicalcium phosphate, crospovidone or croscarmellose sodium, colloidal silicon dioxide, magnesium stearate	Potential for lower-cost, high-throughput manufacturing
Oral solution	Purified water, pH adjuster, preservative, cosolvent or solubilizer, sweetener, flavor	Strongest differentiation opportunity; taste and stability are central
Orally disintegrating tablet	Mannitol, microcrystalline cellulose, crospovidone, low-level lubricant, sweetener and flavor	Potential for dysphagia and geriatric use; bitterness may limit acceptance
Sprinkle or dispersible capsule	Multiparticulate or powder-filled capsule with dispersible carrier	Useful for swallowing difficulty, but dose uniformity and taste require validation

The excipient choices must comply with the FDA Inactive Ingredient Database, applicable compendial standards, and the product’s intended route, dosage form, and maximum daily exposure (FDA, 2024b).

Which excipients are most suitable for nortriptyline hydrochloride capsules?

Hard gelatin capsules remain the lowest-risk platform for a generic nortriptyline hydrochloride product. A conventional formulation can use a water-soluble or partially soluble diluent, a flow aid, and a lubricant.

Recommended capsule formulation architecture

Function	Candidate excipients	Key development issue
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Compatibility, density, fill weight, patient restrictions
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Avoid excessive disintegration variability
Glidant	Colloidal silicon dioxide	Supports uniform powder flow at low dose
Lubricant	Magnesium stearate, sodium stearyl fumarate	Over-lubrication can impair dissolution
Moisture control	Desiccant packaging, low-moisture excipient grades	Important for stability and capsule-shell performance
Capsule shell	Gelatin or hypromellose	Vegetarian positioning and moisture transmission differ

Lactose-based capsules can provide good manufacturability and low cost, but lactose intolerance messaging, aldehyde-related compatibility screening, and patient preference may support a lactose-free product. Microcrystalline cellulose and mannitol can create a cleaner excipient profile but may increase cost or alter powder density.

Nortriptyline hydrochloride is a low-dose active pharmaceutical ingredient in several marketed strengths. Content uniformity is therefore a primary quality attribute. Geometric dilution, ordered mixing, or carrier-based premixes may be necessary to control potency variation, especially in 10 mg and 25 mg products.

What excipients are best for nortriptyline hydrochloride tablets?

Immediate-release tablets can reduce packaging and filling costs compared with capsules. Direct compression is attractive if the active and excipient blend achieves adequate flow, compressibility, and content uniformity.

Direct-compression strategy

A practical platform may combine:

• Microcrystalline cellulose for compactibility.
• Mannitol or lactose for dilution and mouthfeel.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate at controlled concentration.
• Film coating using hypromellose, polyethylene glycol, titanium dioxide, and approved colorants where needed.

Wet granulation may be preferable if the active has poor flow or segregation risk. It introduces water and drying steps that can affect chemical stability, residual moisture, and manufacturing cost. Dry granulation can reduce water exposure but may create harder granules and slower dissolution if compression force is not controlled.

The principal commercial advantage of a tablet is not therapeutic differentiation. It is production efficiency, unit-dose packaging flexibility, and the potential to create scored or smaller units for dose titration. Any scoring claim requires demonstration that the divided portions meet applicable dose-uniformity expectations.

How can an oral liquid create commercial value for nortriptyline hydrochloride?

An oral liquid is the most credible differentiated product opportunity. It can address patients who cannot swallow capsules or tablets, including some older adults, patients with neurologic disease, and selected pediatric or adolescent populations where a clinician determines use is appropriate.

Formulation requirements

Nortriptyline hydrochloride oral liquid development must resolve four issues:

1. Solubility and pH control. The salt form can support aqueous formulation, but pH adjustment may affect solubility, taste, and preservative performance.
2. Bitterness. Tricyclic antidepressants generally require aggressive taste masking. Sweeteners alone may not be sufficient.
3. Chemical and microbial stability. The formulation needs preservative efficacy, container-closure compatibility, and in-use stability data.
4. Dose-measurement accuracy. An oral syringe is preferable to a household teaspoon and can support titration across several dose levels.

Potential excipients include glycerin, sorbitol, propylene glycol, polysorbate 80, citrate or phosphate buffers, sodium benzoate or potassium sorbate, sucralose, saccharin sodium, and flavor systems. Each requires compatibility and regulatory review. Polyols can create gastrointestinal effects. Propylene glycol exposure must be assessed for vulnerable populations. Benzoate preservatives require particular attention in pediatric formulations.

A concentrated liquid may lower bottle size and shipping costs, but it increases the risk of dosing errors. A lower-concentration product can improve measurement accuracy while increasing preservative burden, packaging volume, and shipping weight.

What formulation patents could protect a nortriptyline hydrochloride product?

A new nortriptyline formulation could obtain patent protection only if it satisfies novelty, nonobviousness, written-description, and enablement requirements. The active ingredient itself is old, so the most plausible claim categories are:

• A specific pH and solvent system.
• A stable aqueous composition with defined impurity limits.
• Taste-masked particles or coated multiparticulates.
• A controlled-release matrix or coated pellet.
• A particular polymorph, particle-size distribution, or salt form if legally and technically distinct.
• A container-closure system that preserves stability.
• A defined method of treatment using a differentiated dosage form.

Broad claims covering routine excipients such as a generic sweetener, binder, lubricant, or buffer are vulnerable to obviousness challenges. A stronger formulation patent would link the excipient combination to an unexpected result, such as materially improved stability, reduced bitterness, faster disintegration without dose dumping, or improved bioequivalence.

What is the Orange Book status of nortriptyline hydrochloride?

Nortriptyline hydrochloride is a long-established generic active ingredient. The commercial opportunity is therefore generally based on an abbreviated new drug application, product quality, supply reliability, or differentiated dosage form rather than a new-molecule exclusivity strategy.

The FDA Orange Book identifies reference listed drugs and patent or exclusivity information for approved products. Product-specific Orange Book review is required before launch because listed patents and regulatory exclusivity can differ by dosage form and sponsor (FDA, 2024c).

Protection type	Relevance to nortriptyline hydrochloride
New chemical entity exclusivity	Not expected for this legacy active
Standard innovator patent estate	Limited commercial relevance for conventional generic capsules
Paragraph IV certification	Potentially relevant only if a listed patent applies to the selected reference product
Formulation patent	Relevant to a new liquid, ODT, controlled-release, or taste-masked product
Method-of-use patent	Potentially relevant if a sponsor obtains claims for a new indication
Pediatric exclusivity	Not inherent; would require a qualifying FDA process
Biosimilar exclusivity	Not applicable because nortriptyline is a small-molecule drug

When does nortriptyline hydrochloride lose exclusivity?

Conventional nortriptyline hydrochloride products are already in the mature generic market. The practical launch barrier is usually ANDA approval, manufacturing readiness, bioequivalence, and commercial economics rather than loss of basic active-ingredient exclusivity.

For a differentiated product, the relevant timeline would be created by the sponsor’s own formulation patents, regulatory exclusivity, or both. A 505(b)(2) strategy may be available for a reformulated product when the sponsor relies partly on existing safety and efficacy information but introduces a meaningful change in dosage form, route, formulation, or use. The precise pathway depends on the proposed product and reference listed drug (FDA, 2023).

What generic entry risks exist for nortriptyline hydrochloride?

Generic entry risk is high for standard capsules and immediate-release tablets because:

• The active ingredient is old and widely known.
• Multiple suppliers can manufacture conventional oral products.
• Excipient systems are generally nonproprietary.
• Physicians and pharmacies are familiar with generic substitution.
• Price competition can be severe.
• Product-level revenue is rarely disclosed by private-label or multisource suppliers.

A new formulation faces different risks. A liquid, ODT, or modified-release product may have fewer direct competitors, but development costs, taste failure, stability problems, and uncertain reimbursement can reduce returns.

How strong is the patent estate for nortriptyline hydrochloride?

The patent estate is weak for the unmodified active ingredient and conventional immediate-release products. Patent strength can improve for a formulation with measurable technical advantages, but the claims must be narrow enough to survive validity challenges and broad enough to deter straightforward design-around.

Product concept	Patent strength	Commercial attractiveness
Conventional capsule	Low	Low to moderate
Conventional tablet	Low	Low to moderate
Lactose-free capsule	Low	Limited differentiation
Oral solution with stability and taste-masking data	Moderate	Moderate to high
ODT with demonstrated taste and disintegration advantage	Moderate	Moderate
Controlled-release formulation	Moderate to high if technically successful	Uncertain; requires clinical and PK support
Pediatric liquid with dosing device	Moderate	Moderate, subject to market size
Novel indication	Potentially high	Dependent on clinical evidence and payer acceptance

Which commercial opportunities are most attractive?

1. Ready-to-use oral solution

This is the clearest opportunity where an approved, stable, palatable liquid is not broadly available. The product could compete on pharmacy convenience, oral-syringe dosing, and use in dysphagia populations.

2. High-quality low-cost capsule platform

A manufacturer can improve margins through reliable content uniformity, domestic or dual-source manufacturing, and reduced recalls. This is an operational opportunity rather than a patent-led opportunity.

3. Orally disintegrating tablet

An ODT could target patients with swallowing difficulty and reduce dependence on water. Taste masking is the technical gate. A successful ODT may support a 505(b)(2) or formulation-patent strategy, but the market is likely smaller than the conventional capsule market.

4. Pediatric or titration-focused presentation

Low-strength units, an oral syringe, and clear dose-volume labeling could support careful titration. Nortriptyline carries clinically important anticholinergic, cardiovascular, and central nervous system risks, so the product would need disciplined labeling and dosing controls (FDA, 2024a).

5. Contract manufacturing and private-label supply

Because the molecule is mature, reliable supply can be commercially valuable. Opportunities include dual-source API qualification, low-minimum-order manufacturing, hospital procurement contracts, and backup supply for wholesalers.

What regulatory and manufacturing barriers matter most?

FDA approval depends on dosage-form-specific requirements. For an ANDA, the applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For a new formulation, the sponsor may need additional pharmacokinetic, clinical, stability, or human-factors evidence.

Key manufacturing controls include:

• Assay and content uniformity at every strength.
• Dissolution performance across relevant pH conditions.
• Control of blend segregation.
• Impurity and degradation-product monitoring.
• Capsule-shell or bottle compatibility.
• Light and moisture protection.
• Preservative effectiveness for liquids.
• In-use stability after opening.
• Accurate oral-syringe dose delivery.
• Control of extractables and leachables for liquid packaging.

The principal intellectual-property barrier is likely to be a sponsor’s formulation or device patent, not the underlying nortriptyline molecule. Geographic opportunity is strongest in markets where oral liquids, low-cost psychiatric medicines, or reliable generic supply are underserved. U.S. entry remains price-sensitive; selected emerging markets may reward local manufacturing, smaller pack sizes, and pharmacy-friendly liquid presentations.

How does nortriptyline hydrochloride compare with competing antidepressants?

Nortriptyline competes with SSRIs, SNRIs, other tricyclic antidepressants, and generic CNS products. Its commercial position is weaker in first-line depression because of tolerability and safety concerns, but it retains use in selected patients and in some pain-management settings.

Attribute	Nortriptyline hydrochloride	SSRIs	SNRIs
Market maturity	Highly mature generic	Mature to highly mature	Mature
Formulation differentiation	Available but limited	More common across brands and generics	Moderate
Safety-driven prescribing	Restrictive in some populations	Generally broader first-line use	Depends on product
Commercial pricing	Low in standard forms	Low for most generics	Low to moderate
Biosimilar exposure	None	None	None
Best excipient opportunity	Liquid, ODT, dose-flexible products	Product-specific	Product-specific

What litigation and settlement issues affect nortriptyline hydrochloride?

No biologic litigation or biosimilar settlement framework applies. For conventional nortriptyline products, litigation exposure is more likely to involve manufacturing quality, labeling, product liability, or a later formulation patent than a foundational composition-of-matter patent.

A sponsor developing a differentiated product should monitor:

• Orange Book-listed patents for the selected reference product.
• Paragraph IV certifications filed by ANDA applicants.
• Patent term adjustment and patent-term extension records.
• Abbreviated litigation under the Hatch-Waxman framework.
• License agreements covering taste-masking technology, drug-delivery systems, or manufacturing know-how.
• Settlement provisions affecting launch dates or authorized-generic supply.

Publicly disclosed licensing activity is unlikely to be a central value driver for conventional nortriptyline hydrochloride. Proprietary excipient, coating, or device licenses may matter for a reformulated product.

Key Takeaways

• Nortriptyline hydrochloride is a mature generic active with limited value from a standard capsule or tablet alone.
• The strongest excipient-led opportunity is a stable, palatable, ready-to-use oral liquid.
• ODT, dispersible, and low-strength titration formats offer secondary differentiation paths.
• Content uniformity, taste masking, dissolution, and liquid stability are the main technical risks.
• Conventional products face high generic competition and weak underlying patent protection.
• Formulation patents need specific technical evidence, not routine excipient combinations.
• A 505(b)(2) strategy may be relevant for a differentiated dosage form, depending on the product design.
• Biosimilar risk is not applicable.
• Commercial value is more likely to come from improved usability, reliable supply, and targeted distribution than from molecule-level exclusivity.

FAQs

Is nortriptyline hydrochloride suitable for an oral suspension?

Yes. An oral suspension may be feasible where an aqueous solution is difficult to stabilize or where a concentrated liquid is preferred. The formulation must control sedimentation, redispersibility, dose uniformity, taste, and preservative performance.

Can a lactose-free nortriptyline capsule create meaningful market exclusivity?

Usually not by itself. Lactose-free positioning can support patient or procurement preferences, but the excipient change is unlikely to provide strong patent protection without an unexpected technical benefit.

Does nortriptyline hydrochloride require a controlled-release formulation?

No. Immediate-release products are established. Controlled release could reduce dosing frequency or peak-related tolerability, but it would require substantial pharmacokinetic and clinical justification.

Which packaging is best for a nortriptyline hydrochloride oral liquid?

An amber bottle with a child-resistant closure and a calibrated oral syringe is generally the most practical platform. The final selection depends on light stability, adsorption, extractables, preservative compatibility, and in-use stability.

Can a nortriptyline formulation be protected through an excipient patent?

Yes, but protection is more credible when the excipient system produces a demonstrated technical effect, such as improved chemical stability, reduced bitterness, controlled release, or reliable dose delivery. Routine substitution of one filler or lubricant for another is generally weak patent subject matter.

References

1. DailyMed. (2024a). Pamelor- nortriptyline hydrochloride capsule. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024a). Nortriptyline hydrochloride prescribing information. https://www.accessdata.fda.gov/

4. U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

5. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book